Key Takeaway: Foghorn Therapeutics announced its participation in three upcoming investor conferences, including the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. The company focuses on developing innovative treatments for serious diseases through its Gene Traffic Control platform, particularly in oncology. Presentations will be available via webcast on their website.
Price reaction · baseline $4.41 (2025-10-31 close) · hit pre-market · 1 other FHTX headline(s) in the window, move may be shared
day 0 close · peak
-4.5%
Market Sentiment Analysis
POSITIVE FACTORS
Foghorn Therapeutics is participating in three notable investor conferences.
The company is pioneering a new class of medicines targeting serious diseases.
Their Gene Traffic Control platform has the potential to transform lives.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+56%
120-day peak, hindsight
Typical move
5.9%
average across 4 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
FHD-286
Phase 2 · Small Cell Lung Cancer
Full Press Release Details
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn®Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Guggenheim Second Annual Healthcare Innovation Conference
Stifel 2025 Healthcare Conference
Jefferies 2025 London Healthcare Conference
A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.
About Foghorn TherapeuticsFoghorn®Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control®platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website atwww.foghorntx.comfor more information on the Company, and follow us onXandLinkedIn.